Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Array Biopharma Inc    ARRY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Array Biopharma Inc : Morning Research on Sanofi, Keryx Biopharma, VIVUS, and Array BioPharma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/27/2013 | 01:05pm CET

LONDON, March 27, 2013 /PRNewswire/ --

Drug manufacturers and biotechnology companies are adapting to the changing market dynamics for the healthcare industry. One of the major trends to emerge in the healthcare industry in the last year has been increasing competition from generic drugs. For companies such as Sanofi SA (NYSE: SNY), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), VIVUS Inc. (NASDAQ: VVUS), and Array Biopharma Inc. (NASDAQ: ARRY), the key will be to boost their product pipeline in the wake of increasing generic competition. Meanwhile, the healthcare industry is also evaluating the impact of President Obama's Affordable Care Act (ACA), which was upheld by the Supreme Court last year. Healthcare stocks ended on a mixed note on Tuesday even as the broad market rallied, with the Dow Jones closing at yet another record high. StockCall has posted free technical research reports on SNY, KERX, VVUS, and ARRY and these can be accessed by signing up at

http://www.stockcall.com/analysis

Shares of Sanofi SA rose sharply in trading on Tuesday, tracking gains in the broad market. The stock rose to an intra-day high of $50.73 before finishing the day 1.08% higher at $50.54 on above average volume of 3.46 million. Sanofi's shares are currently trading close to their 52-week high of $50.93. The stock has gained more than 6.60% so far in 2013. The company's shares are also trading well above their 50-day and 200-day moving averages, which is a bullish signal. Download the free report on SNY upon registration at

http://www.StockCall.com/SNY032713.pdf

Keryx Biopharmaceuticals Inc.'s shares struggled in Tuesday's trading session, extending their losses from previous trading session. The stock finished the day 1% lower at $6.90 on volume of 1.35 million, taking its gains in the last three sessions to 1.85%. Keryx's shares have had an excellent run so far in 2013, gaining more than 163%. The gains came in late January; however, since then the stock has struggled. Its MACD is currently trading below the signal line, which is a bearish signal. KERX technical report can be accessed for free by signing up at

http://www.StockCall.com/KERX032713.pdf

Shares of VIVUS Inc. fell sharply in trading on Tuesday even as the broad market rallied. VIVUS' shares fell to an intra-day low of $10.39 before finishing the day 2.83% lower at $10.63 on volume of 2.09 million. The company's shares have been facing stiff resistance at $11. The stock currently has support at $10. The stock's MACD chart is currently trading below the zero-line, which is a bearish signal. The stock is also trading well below its 50-day and 200-day moving averages, which further confirms the bearish trend. The free report on VVUS can be downloaded by signing up now at

http://www.StockCall.com/VVUS032713.pdf

Shares of Array Biopharma Inc. rallied in trading on Tuesday, closing 6.25% higher at $4.93 on above average volume of 1.26 million. Array's shares have now gained more than 32.50% for the year, outperforming the S&P 500, which has gained more than 9.60% in the same period. The stock has seen a series of highs in the last few sessions, which is a bullish signal. The stock has also broken through $4.50 resistance level, which further confirms the positive trend. Free report on ARRY can be accessed by registering at

http://www.StockCall.com/ARRY032713.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARRAY BIOPHARMA INC
01/06 ARRAY BIOPHARMA : Patent Issued for Quinazoline Analogs as Receptor Tyrosine Kin..
01/03 ARRAY BIOPHARMA : To Present At The Annual J.P. Morgan Healthcare Conference
2016 ARRAY BIOPHARMA INC. (NASDAQ : ARRY) Files An 8-K Entry into a Material Definiti..
2016 ARRAY BIOPHARMA INC : Entry into a Material Definitive Agreement, Termination of..
2016 BEST BIOTECH STOCKS 2016 : The NASDAQ’s Top-Performers
2016 ARRAY BIOPHARMA : Assigned Patent
2016 ARRAY BIOPHARMA : To Present At The Piper Jaffray Annual Healthcare Conference
2016 5 TOP NASDAQ BIOTECH STOCKS : Ocular Therapeutix Gains Near 60 Percent
2016 ARRAY BIOPHARMA : Assigned Patent
2016 ARRAY BIOPHARMA : Reports Financial Results For The First Quarter Of Fiscal 2017
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Dragon Of The Market - Small Cap Stocks Breathe Fire!
01/12 Array Biopharma (ARRY) Presents At 35th Annual J.P. Morgan Healthcare Confere..
01/09 After Hours Gainers / Losers
01/09 Big day for Oncology players after Ariad sale, Merck/Incyte deal
01/09 BIOTECHNOLOGY : Is 2017 Going To Be Any Better?